| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/01/2025 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 07/01/2025 | 20:52 | Edgar (US Regulatory) | Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 27/12/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 20/12/2024 | 12:27 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 11/12/2024 | 14:29 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 06/12/2024 | 12:16 | Edgar (US Regulatory) | Form S-4/A - Registration of securities, business combinations: [Amend] | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 14/11/2024 | 22:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 14/11/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 12/11/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 12/11/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 11/11/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes B | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 01/10/2024 | 23:22 | Edgar (US Regulatory) | Form S-4 - Registration of securities, business combinations | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 26/09/2024 | 22:45 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 19/09/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences Announces 1-for-58 Reverse Stock Split | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 14/08/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 13/08/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 09/07/2024 | 18:13 | GlobeNewswire Inc. | Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND” | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 09/07/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 15/05/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 14/05/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 01/04/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 28/03/2024 | 13:31 | GlobeNewswire Inc. | ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 04/03/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 22/02/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 24/01/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 17/01/2024 | 00:11 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 05/01/2024 | 22:14 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 20/12/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 12/12/2023 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 21/11/2023 | 14:06 | GlobeNewswire Inc. | ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds | NASDAQ:RSLS | ReShape Lifesciences Inc |